Watanabe T, Suga T
J Pharmacobiodyn. 1985 Dec;8(12):1060-7. doi: 10.1248/bpb1978.8.1060.
Effects of tolmetin, diclofenac Na, fenbufen, alclofenac, aminopyrine, mepirizole, thiaramide and aspirin as a positive control, which are widely used in this country as anti-inflammatory drugs, and on body and liver weights, triglyceride and cholesterol level and hepatic peroxisomal enzymes of normolipemic rats were examined. All of these drugs except diclofenac Na affected the enzyme composition of hepatic peroxisomes. Tolmetin (100 mg/kg) and fenbufen (50 mg/kg) increased carnitine acetyltransferase (CAT) and fatty acyl-coenzyme A oxidizing system (FAOS) activities, which participate in hepatic lipid metabolism. The latter also increased the activity of D-amino acid oxidase slightly. Alclofenac (300 mg/kg) increased the activities of FAOS, CAT and carnitine palmitoyltransferase which has been known as the rate-limiting enzyme of fatty acid oxidation in mitochondria, and decreased those of catalase and urate oxidase. Aminopyrine (300 mg/kg) increased the activities of catalase and FAOS. However, none of the above drugs influenced liver weight, serum or liver lipid levels. Mepirizole (300 mg/kg) increased the activities of FAOS and CAT about 2-fold, whereas the activities of catalase and urate oxidase and serum triglyceride level were decreased. Furthermore, these drugs showed no enhancement of the biosynthesis of peroxisome proliferation associated polypeptide having a molecular weight of 80000. From these results, it is concluded that although these drugs have an influence on the enzyme composition of hepatic peroxisomes, they may not induce the peroxisome population in hepatic cells. Thus, the possibility of hepatocarinogenicity and lipid lowering effect through the peroxisome-proliferation would be excluded.
研究了托美丁、双氯芬酸钠、芬布芬、阿氯芬酸、氨基比林、美吡唑、噻酰胺以及作为阳性对照的阿司匹林(在该国广泛用作抗炎药)对正常血脂大鼠的体重、肝脏重量、甘油三酯和胆固醇水平以及肝脏过氧化物酶体酶的影响。除双氯芬酸钠外,所有这些药物均影响肝脏过氧化物酶体的酶组成。托美丁(100毫克/千克)和芬布芬(50毫克/千克)增加了参与肝脏脂质代谢的肉碱乙酰转移酶(CAT)和脂肪酰辅酶A氧化系统(FAOS)的活性。后者还略微增加了D-氨基酸氧化酶的活性。阿氯芬酸(300毫克/千克)增加了FAOS、CAT和肉碱棕榈酰转移酶(已知为线粒体脂肪酸氧化的限速酶)的活性,并降低了过氧化氢酶和尿酸氧化酶的活性。氨基比林(300毫克/千克)增加了过氧化氢酶和FAOS的活性。然而,上述药物均未影响肝脏重量、血清或肝脏脂质水平。美吡唑(300毫克/千克)使FAOS和CAT的活性增加了约2倍,而过氧化氢酶和尿酸氧化酶的活性以及血清甘油三酯水平则降低。此外,这些药物未显示出对分子量为80000的过氧化物酶体增殖相关多肽生物合成的增强作用。从这些结果可以得出结论,尽管这些药物对肝脏过氧化物酶体的酶组成有影响,但它们可能不会诱导肝细胞中的过氧化物酶体数量增加。因此,可以排除通过过氧化物酶体增殖产生肝致癌性和降脂作用的可能性。